What is a best-selling drug worth? In 2013, at least, it came down to at least $3 billion in annual sales—triple the $1 billion benchmark that has long defined “blockbuster” treatments.
Even then, $3 billion only gets your drug on the bottom of GEN’s top 25 best-selling drugs list for 2013. Among the top three disease categories, six best-selling drugs have indications for forms of cancer, four for arthritis, and three for diabetes. Four indications—asthma/COPD, heart disease, HIV, and neurological—are each represented on the list by two best sellers.
This year’s list ranks drugs based on sales or revenue reported by biopharma companies in press announcements, annual reports, investor materials, and conference calls during 2013. Each drug is listed by name, sponsor(s), diseases indicated, 2013 sales, 2012 sales, the percentage change between both years, and fourth-quarter figures for 2013 and 2012. The patent cliff knocked out from this year’s list three best sellers of 2012—Plavix (#11, Sanofi and Bristol-Myers Squibb), Lipitor (#15, Pfizer), and Singulair (#17, Merck & Co.).